Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy, tolerability, and safety of brexpiprazole as adjunctive therapy to antidepressant treatments (ADTs) in adults with major depressive disorder (as defined by DSM-IV-TR criteria) and inadequate response to ADTs. METHOD: Patients with historical inadequate response to 1-3 ADTs were enrolled. All patients entered a prospective 8-week phase on physician-determined, open-label ADT. Those with inadequate response were randomized to ADT + brexpiprazole 2 mg/d or ADT + placebo for 6 weeks. The study was conducted between July 2011 and May 2013. The primary efficacy end point was change from baseline to week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The key secondary end point was change from baseline to week 6 in Sheehan Disability Scale (SDS) mean score. The efficacy population comprised all patients who had ≥ 1 dose of study drug in the double-blind phase and both baseline and ≥ 1 postrandomization MADRS scores. The efficacy population per final protocol included patients from the efficacy population who met amended randomization criteria of inadequate response throughout prospective treatment. RESULTS: Brexpiprazole (n = 175) reduced mean MADRS total score versus placebo (n = 178) at week 6 in the efficacy population per final protocol (-8.36 vs -5.15, P = .0002). Brexpiprazole improved SDS mean score versus placebo (-1.35 vs -0.89, P = .0349). The most common treatment-related adverse events were weight gain (brexpiprazole, 8.0%; placebo, 3.1%) and akathisia (7.4% vs 1.0%). CONCLUSIONS: Adjunctive brexpiprazole therapy demonstrated efficacy and was well tolerated in patients with major depressive disorder and inadequate response to ADTs. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01360645.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Wilamowska (2010) · doi:10.1001/archpsyc.1988.01800320058007 · Cited by 2,115
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Self-citationMcIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433
Velligan, D. I., Sajatovic, M., Hatch, A., Kramata, P., & Docherty, J. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s124658 · Cited by 333
“Thirteen studies analyzed the relationship between substance abuse and adherence: 6 were prospective, 7 were cross-sectional, and all demonstrated a significant association.”
McAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.023 · Cited by 278
Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.134 · Cited by 215
Kishi, T., Sakuma, K., Nomura, I., Matsuda, Y., Mishima, K., & Iwata, N. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz040 · Cited by 180
Ward, K., & Citrome, L. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s169369 · Cited by 181
Maletic, V., Eramo, A., Gwin, K., Offord, S. J., & Duffy, R. A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00042 · Cited by 166
“In phase II and III studies, brexpiprazole was efficacious in the treatment of patients with schizophrenia (37), and when administered adjunctively in patients with MDD and an inadequate response to ADTs (38).”
BackgroundThase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Zhang, P., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09689 · Cited by 165
Self-citationNemeroff, C. B. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20060845 · Cited by 152
Pharmacological Treatments for Patients with Treatment-Resistant Depression
Ruberto, V. L., Jha, M. K., & Murrough, J. W. (2020) · Pharmaceuticals · doi:10.3390/ph13060116 · Cited by 147
“Hobart et al., 2018 [41] Quetiapine plus antidepressant; Brexpiprazole plus antidepressant; placebo plusantidepressant Mahmoud et al., 2007 [47] Risperidone plus antidepressant; placebo plus antidepressant Reeves et al., 2008 [46] Risperidone plus antidepressant; placebo plus antidepressant Keitner et al., 2009 [48] R…”
BackgroundInfluentialCorponi, F., Fabbri, C., Bitter, I., Montgomery, S., Vieta, E., Kasper, S., Pallanti, S., & Serretti, A. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.06.008 · Cited by 146
“Two studies (Thase et al., 2015a; Thase et al., 2015b) established brexpiprazole efficacy as adjunctive therapy to antidepressant treatment in MDD patients who failed at least one previous adequate antidepressant trial, with a pooled NNT of 12 (95% CI 8-26) (Citrome, 2015b) (Table 4).”
BackgroundAugmentation therapies for treatment-resistant depression: systematic review and meta-analysis
Strawbridge, R., Carter, B., Marwood, L., Bandelow, B., Tsapekos, D., Nikolova, V. L., Taylor, R., Mantingh, T., de Angel, V., Patrick, F., et al. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.233 · Cited by 140
Frankel, J. S., & Schwartz, T. L. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316672136 · Cited by 133
Jones, B. D. M., Razza, L. B., Weissman, C. R., Karbi, J., Vine, T., Mulsant, L. S., Brunoni, A. R., Husain, M. I., Mulsant, B. H., Blumberger, D. M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.25531 · Cited by 121
Evidence-based pharmacotherapy of treatment-resistant unipolar depression
Dold, M., & Kasper, S. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1248852 · Cited by 118
“Recently published phase 3 studies suggest efficacy of the new drug application brexpiprazole in treatment-resistant MDD and the official approval for this indication is sought for this substance (Thase et al. 2015).”
BackgroundJha, M. K., & Mathew, S. J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230025 · Cited by 114
Citrome, L. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12752 · Cited by 107
Vázquez, G. H., Bahji, A., Undurraga, J., Tondo, L., & Baldessarini, R. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013579 · Cited by 95
Das, S., Barnwal, P., Aruldhas, B. W., Mondal, S., & Saha, I. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315614739 · Cited by 92
Fava, M., Thase, M. E., Trivedi, M. H., Ehrich, E., Martin, W. F., Memisoglu, A., Nangia, N., Stanford, A. D., Yu, M., & Pathak, S. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0284-1 · Cited by 80
Self-citationNeuropharmacological classification of antidepressant agents based on their mechanisms of action
Fasipe, O. (2018) · Archives of Medicine and Health Sciences · doi:10.4103/amhs.amhs_7_18 · Cited by 80
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
Investigational drugs in recent clinical trials for treatment-resistant depression
Garay, R. P., Zarate, C. A., Charpeaud, T., Citrome, L., Correll, C. U., Hameg, A., & Llorca, P.-M. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1283217 · Cited by 74
“on a clinical development program that included two acute phase pivotal Phase III placebo-controlled trials [110,111].”
MethodPharmacological interventions for treatment-resistant depression in adults
Davies, P., Ijaz, S., Williams, C. J., Kessler, D., Lewis, G., & Wiles, N. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010557.pub2 · Cited by 73
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia
Keks, N. A., Hope, J., Schwartz, D., McLennan, H., Copolov, D., & Meadows, G. N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00718-4 · Cited by 78
“Studies to date have not extensively explored the specific implications for sexual dysfunction during antipsychotic treatment in schizophrenia, which may not be readily reported as an adverse effect (a study of adjunctive brexpiprazole in major depression found comparable sexual satisfaction improvement between brexpi…”
BackgroundCaldiroli, A., Capuzzi, E., Tagliabue, I., Capellazzi, M., Marcatili, M., Mucci, F., Colmegna, F., Clerici, M., Buoli, M., & Dakanalis, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313070 · Cited by 70
“Two RCTs conducted on large samples by Thase and his group [41,42] demonstrated the superiority of brexpiprazole over a placebo at the highest dosages of 2 or 3 mg/day, but not at 1 mg/day.”
BackgroundMa, M., Ren, Q., Yang, C., Zhang, J.-C., Yao, W., Dong, C., Ohgi, Y., Futamura, T., & Hashimoto, K. (2017) · Psychopharmacology · doi:10.1007/s00213-016-4483-7 · Cited by 69
Hobart, M., Skuban, A., Zhang, P., Josiassen, M. K., Hefting, N., Augustine, C., Brewer, C., Sanchez, R., & McQuade, R. D. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1430220 · Cited by 63
Self-citationCitrome, L., Stensbøl, T. B., & Maeda, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1086269 · Cited by 63
“Brexpiprazole’s complex pharmacology at noradrenergic receptors at subnanomolar and nanomolar affinities may have implications for the molecule’s antidepressant effects [65], made relevant by its approval as an adjunctive therapy for the treatment of MDD based on results from a successful Phase III program [66,67].”
BackgroundMa, M., Ren, Q., Yang, C., Zhang, J.-C., Yao, W., Dong, C., Ohgi, Y., Futamura, T., & Hashimoto, K. (2016) · Scientific Reports · doi:10.1038/srep39209 · Cited by 59
Fava, M., Durgam, S., Earley, W., Lu, K., Hayes, R., Laszlovszky, I., & Németh, G. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000235 · Cited by 58
“…or brexipiprazole augmentation trials with similar study designs (Berman et al., 2007, 2009; Marcus et al., 2008; Kamijima et al., 2013; Lenze et al., 2015; Thase et al., 2015a, 2015b), and high placebo response can reduce signal detection, which may lead to negative results (Fava et al., 2003).”
BackgroundThe emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents
Fasipe, O. J. (2019) · IBRO Reports · doi:10.1016/j.ibror.2019.01.001 · Cited by 63
Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
Wang, S.-M., Han, C., Lee, S.-J., Jun, T.-Y., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.3.159 · Cited by 56
“The two studies were identical in design and were conducted by the same research group.(17,18) In both studies, subjects included had a history of inadequate response to 1-3 treatment trials of standard antidepressant medications for their current depressive episode.”
ResultKishimoto, T., Hagi, K., Kurokawa, S., Kane, J., & Correll, C. (2022) · Psychological Medicine · doi:10.1017/s0033291722000745 · Cited by 34
Demyttenaere, K., Detraux, J., Racagni, G., & Vansteelandt, K. (2019) · CNS Drugs · doi:10.1007/s40263-019-00625-3 · Cited by 56
Carter, B., Strawbridge, R., Husain, M. I., Jones, B. D. M., Short, R., Cleare, A. J., Tsapekos, D., Patrick, F., Marwood, L., Taylor, R. W., et al. (2020) · International Review of Psychiatry · doi:10.1080/09540261.2020.1765748 · Cited by 47
Roméo, B., Blecha, L., Locatelli, K., Benyamina, A., & Martelli, C. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118760661 · Cited by 52
Treating depression with adjunctive antipsychotics
Mulder, R., Hamilton, A., Irwin, L., Boyce, P. M., Morris, G., Porter, R., & Malhi, G. S. (2018) · Bipolar Disorders · doi:10.1111/bdi.12701 · Cited by 44
Earley, W. R., Guo, H., Németh, G., Harsányi, J., & Thase, M. E. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4578 · Cited by 44
Self-citationBrexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders
Siwek, M., Wojtasik-Bakalarz, K., Krupa, A. J., & Chrobak, A. A. (2023) · Brain Sciences · doi:10.3390/brainsci13030397 · Cited by 50
“[47] N = 379; TRD; 6 weeks; BRX * 2 mg vs.”
Brexpiprazole: First Global Approval
Greig, S. L. (2015) · Drugs · doi:10.1007/s40265-015-0462-2 · Cited by 42
“05) increases from baseline in mean Simpson-Angus Scale and Barnes Akathisia Rating Scale (BARS) scores with adjunctive brexpiprazole 2 mg/day versus adjunctive placebo in PYXIS [11], and in mean BARS and Abnormal Involuntary Movement Scale scores with adjunctive brexpiprazole 3 mg/day versus adjunctive placebo in POL…”
BackgroundMethodInfluentialBrexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
Diefenderfer, L. A., & Iuppa, C. A. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.09.207 · Cited by 44
“Small increases in prolactin were seen in both trials, along with small changes in lipid and other metabolic measures.(9,10)”
Grigolon, R. B., Trevizol, A. P., Gerchman, F., Bambokian, A. D., Magee, T., McIntyre, R. S., Gomes, F. A., Brietzke, E., & Mansur, R. B. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.03.032 · Cited by 35
McEvoy, J. P., & Citrome, L. (2016) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.mcci.010316 · Cited by 38
Brexpiprazole for treatment-resistant major depressive disorder
Fornaro, M., Fusco, A., Anastasia, A., Cattaneo, C. I., & Berardis, D. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1654457 · Cited by 39
“The pivotal trials of brexpiprazole for MDD had difficulty showing efficacy to the FDA based on the original analysis plan, and they had to create an amended analysis plan excluding study subjects with variable response to demonstrate significant efficacy [23,24].”
BackgroundMethodResultInfluentialAkathisia and Newer Second‐Generation Antipsychotic Drugs: A Review of Current Evidence
Chow, C. L., Kadouh, N. K., Bostwick, J. R., & VandenBerg, A. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2404 · Cited by 40
McIntyre, R. S., Weiller, E., Zhang, P., & Weiss, C. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.013 · Cited by 36
Self-citationRecent advances in dopamine D 2 receptor ligands in the treatment of neuropsychiatric disorders
Jůza, R., Musílek, K., Mezeiová, E., Soukup, O., & Korábečný, J. (2022) · Medicinal Research Reviews · doi:10.1002/med.21923 · Cited by 37
Björkholm, C., Marcus, M. M., Konradsson‐Geuken, Å., Jardemark, K. E., & Svensson, T. H. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.01.014 · Cited by 35
Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management
Salem, H., Pigott, T. A., Zhang, X. Y., Zeni, C., & Teixeira, A. L. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1361322 · Cited by 34
“Brexpiprazole exhibited higher risk of developing movement disorders, mainly akathisia, when compared to placebo group [89,90].”
BackgroundClinical role of brexpiprazole in depression and schizophrenia
Parikh, N., Robinson, D., & Clayton, A. H. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s94060 · Cited by 31
“26, respectively.(23,24) A pooled analysis showed an overall 23.”
BackgroundFava, M., Freeman, M. P., Flynn, M., Hoeppner, B. B., Shelton, R. C., Iosifescu, D. V., Murrough, J. W., Mischoulon, D., Cusin, C., Rapaport, M. H., et al. (2017) · Brain stimulation · doi:10.1016/j.brs.2017.09.010 · Cited by 34
“Food and Drug Administration (FDA) for adjunctive treatment in patients with TRD: aripiprazole [6], quetiapine [7], olanzapine-fluoxetine combination [8] and brexpiprazole [9].”
BackgroundThase, M. E., Zhang, P. G. Y., Weiss, C., Meehan, S. R., & Hobart, M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1638913 · Cited by 34
Self-citationA New Paradigm for Achieving a Rapid Antidepressant Response
Malhi, G. S., Morris, G., Bell, E., & Hamilton, A. (2020) · Drugs · doi:10.1007/s40265-020-01303-1 · Cited by 34
Thase, M. E., Weiller, E., Zhang, P. G. Y., Weiss, C., & McIntyre, R. S. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s185815 · Cited by 32
Self-citationKamiya, M., Sabia, H. D., Marella, J., Fava, M., Nemeroff, C. B., Umeuchi, H., Iijima, M., Chaki, S., & Nishino, I. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.05.017 · Cited by 28
Pharmacotherapy for Treatment-Resistant Depression
Vas, C., Jain, A., Trivedi, M., Jha, M. K., & Mathew, S. J. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.012 · Cited by 32
Hobart, M., Zhang, P. G. Y., Skuban, A., Brewer, C., Hefting, N., Sanchez, R., & McQuade, R. D. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001034 · Cited by 30
Self-citationBauer, M., Hefting, N., Lindsten, A., Josiassen, M. K., & Hobart, M. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2018.23 · Cited by 26
“The efficacy and safety of brexpiprazole as adjunctive treatment to ADT over 6 weeks was demonstrated in two pivotal Phase 3, fixed-dose studies in MDD (Pyxis and Polaris) (8,9), and recently also in another fixed-dose study (Sirius) (10) and a flexible-dose study (Delphinus) (11).”
MethodSelf-citationWeiss, C., Meehan, S. R., Brown, T. M., Gupta, C., Mørup, M. F., Thase, M. E., McIntyre, R. S., & Ismail, Z. (2021) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-021-00380-4 · Cited by 25
Self-citationEaves, S. M., & Rey, J. A. (2016) · PubMed · Cited by 28
Brexpiprazole: a new leaf on the partial dopamine agonist branch
Hope, J., Castle, D. J., & Keks, N. A. (2017) · Australasian Psychiatry · doi:10.1177/1039856217732473 · Cited by 26
Vieta, E., Sachs, G. S., Chang, D., Hellsten, J., Brewer, C., Peters-Strickland, T. S., & Hefting, N. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120985102 · Cited by 26
“Email: evieta@clinic.cat At the recommended doses of brexpiprazole in the pivotal Phase III trials in schizophrenia and MDD, discontinuation rates due to adverse events (AEs) were low (Citrome, 2015; Correll et al., 2015; Hobart et al., 2018; Thase et al., 2015).”
BackgroundResultAdjunctive Brexpiprazole: A Review in Major Depressive Disorder
McKeage, K. (2016) · CNS Drugs · doi:10.1007/s40263-016-0320-0 · Cited by 25
Wong, D. F., Raoufinia, A., Bricmont, P., Brašić, J. R., McQuade, R. D., Forbes, R. A., Kikuchi, T., & Kuwabara, H. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03021-9 · Cited by 27
Self-citationDavis, L. L., Ota, A., Perry, P. P., Tsuneyoshi, K., Weiller, E., & Baker, R. A. (2016) · Brain and Behavior · doi:10.1002/brb3.520 · Cited by 25
“In two pivotal Phase III, double- blind, placebo- controlled studies, brexpiprazole 2 and 3 mg day−1 + ADT significantly improved the MADRS total score versus placebo over 6 weeks in patients with MDD and inadequate response to ADTs (Thase et al., 2015a, 2015b).”
BackgroundResultInfluentialMarkovic, M., Gallipani, A., Patel, K. H., & Maroney, M. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028016678262 · Cited by 22
“4%).(12) The other phase 3 trial also assessed the efficacy, safety, and tolerability of brexpiprazole adjunctive to ADTs at doses of 1 and 3 mg.”
BackgroundMethodResultInfluentialD, M. F. M., Okame, T., Matsushima, Y., Perry, P. P., Weiller, E., & Baker, R. A. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw087 · Cited by 23
Yoon, S., Jeon, S. W., Ko, Y., Patkar, A. A., Masand, P. S., Pae, C., & Han, C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000622 · Cited by 21
Antoun, A., Girgis, E., & Mishriky, R. S. L. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000308 · Cited by 20
“…acute management and seven as adjunct in the management of MDD) (Correll et al., 2015; Kane et al., 2015; NCT00905307, 2015; NCT01052077, 2015; Thase et al., 2015a; Thase et al., 2015b; Citrome et al., 2016; NCT00797966, 2016; NCT01810380, 2017; NCT01838681, 2017; NCT02194933, 2018; Hobart et…”
InfluentialOosterhof, C. A., Mansari, M. E., Bundgaard, C., & Blier, P. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv111 · Cited by 21
Hobart, M., Zhang, P. G. Y., Weiss, C., Meehan, S. R., & Eriksson, H. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy095 · Cited by 20
Self-citationMombereau, C., Arnt, J., & Mørk, A. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.12.015 · Cited by 19
“…cortex; 5-HT, u). both drugs have shown low potential for occurrence of extrapyramidal side effects (EPS; Correll et al., 2015; Kane et al., 2015, Thase et al., 2015a, 2015b; Gao et al., 2008; Rummel-Kluge et al., 2012), although a recent explorative study comparing both drugs in patients with…”
Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents
Kannarkat, G. T., Caroff, S. N., & Morley, J. F. (2022) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.695 · Cited by 20
Nelson, J. C., Weiller, E., Zhang, P. G. Y., Weiss, C., & Hobart, M. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.054 · Cited by 19
Self-citationClayton, A. H., Ivkovic, J., Chen, D., George, V., & Hobart, M. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001297 · Cited by 25
Self-citationBrexpiprazole Reduces 5-HT7 Receptor Function on Astroglial Transmission Systems
Fukuyama, K., Motomura, E., & Okada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126571 · Cited by 17
Weisler, R. H., Ota, A., Tsuneyoshi, K., Perry, P. P., Weiller, E., Baker, R. A., & Sheehan, D. V. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.06.001 · Cited by 17
Antipsychotic and anticholinergic drugs
Meltzer, H. Y., & Bobo, W. V. (2020) · doi:10.1093/med/9780198713005.003.0064 · Cited by 16
Adjunctive brexpiprazole for the treatment of major depressive disorder
Beyer, J. L., & Weisler, R. H. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1254188 · Cited by 16
“…agonist Route of administration oral Chemical structure 7-{4-[4-(1-Benzothipphen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1 H)-one Pivotal trial(s) Thase et al 2015a; Thase et al 2015b antidepressant effect of 5HT1A receptor agonists is predominately mediated by postsynaptic 5HT1A receptors,…”
BackgroundMethodInfluentialWeiller, E., Weiss, C., Watling, C. P., Edge, C., Hobart, M., Eriksson, H., & D, M. F. M. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s146840 · Cited by 18
“,34, 35, A summary of the SDS results from the included studies is given in Table 2.”
Self-citationBai, B., Li, Y., Chen, X., Huang, J., Chen, Q., Du, X., Huang, C., & Yang, Y. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-06783-7 · Cited by 15
Seetasith, A., Greene, M., Hartry, A., & Burudpakdee, C. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1484373 · Cited by 15
Mishra, A., Sarangi, S. C., Maiti, R., Sood, M., & Reeta, K. H. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2022 · Cited by 15
Lepola, U., Hefting, N., Zhang, D., & Hobart, M. (2018) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4952 · Cited by 15
Self-citationAdverse Effects of Second-Generation Antipsychotics as Adjuncts to Antidepressants
Thase, M. E. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.04.008 · Cited by 15
Self-citationFurukawa, Y., Oguro, S., Obata, S., Hamza, T., Ostinelli, E. G., & Kasai, K. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13438 · Cited by 14
Davis, L. L., Behl, S., Lee, D. J., Zeng, H., Skubiak, T., Weaver, S., Hefting, N., Larsen, K. G., & Hobart, M. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.3996 · Cited by 23
Self-citationSforzini, L. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100331 · Cited by 15
“…for MDD of medications used in psychosis and directly affecting DA transmission, such as aripiprazole (Marcus et al., 2008) and brexpiprazole (Thase et al., 2015) or the more recent and still under investigation cariprazine (Fava et al., 2018) and pramipexole (Clinical Trials Register.,…”
Amada, N., Hirose, T., Suzuki, M., Kakumoto, Y., Futamura, T., Maeda, K., & Kikuchi, T. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12316 · Cited by 13
Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment
Bruno, C. D., Elmokadem, A., Housand, C., Jordie, E. B., Chow, C. R., LAUGHREN, T. P., & Greenblatt, D. J. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1947 · Cited by 13
Barman, R., Majumder, P., Doifode, T., & Kablinger, A. S. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i12.1228 · Cited by 16
Aftab, A., & Gao, K. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1354849 · Cited by 15
“Significant difference between treatment groups was apparent from the first week onward [38].”
BackgroundResultInfluentialCha, D. S., Luo, X., Ahmed, J., Becirovic, L., Cha, R. H., & McIntyre, R. S. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1653759 · Cited by 13
“The foregoing Phase III clinical trials evaluated the efficacy, safety, and tolerability of brexpiprazole as an adjunctive agent among individuals age 18–65 years of age meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for a major depressive episode…”
BackgroundMethodInfluentialThase, M. E., Ismail, Z., Meehan, S. R., Weiss, C., Régnier, S. A., Larsen, K. G., & McIntyre, R. S. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.02.008 · Cited by 13
Self-citationHoran, W. P., Kalali, A. H., Brannan, S. K., Drevets, W., Leoni, M. J., Mahableshwarkar, A. R., Martin, W. J., Rao, S., Reuteman-Fowler, C., Sauder, C. L., et al. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae151 · Cited by 14
“Notably, pivotal augmentation trials for depressed patients with MDD who had inadequate response to current antidepressant treat-ment have led to approvals with 6 to 8-week trial designs for several different medications, including aripiprazole, 85 brexpiprazaole, 86 and cariprazine.”
D, M. F. M., Weiller, E., Zhang, P. G. Y., & Weiss, C. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000678 · Cited by 13
“Here we assess the efficacy of adjunctive brexpiprazole in patients with MDD and irritability, comparing brexpiprazole to placebo as adjunctive therapy to ADT in patients with and without self-rated irritability, using pooled data from the 2 similarly designed randomized, double-blind, placebocontrolled, pivotal phase…”
MethodSelf-citation
Metadata
- Authors
- Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., & Eriksson, H.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Thase, Michael E.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2015-09-23
- Volume
- 76
- Issue
- 09
- Pages
- 1224-1231
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1868790909
- Cited by
- 182
- References
- 39
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 16 · 2023: 17 · 2022: 12 · 2021: 13 · 2020: 17 · 2019: 15 · 2018: 17 · 2017: 20 · 2016: 24 · 2015: 6
- FWCI
- 16.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- brexpiprazole, major depressive disorder, adjunctive therapy, antidepressant response, inadequate response to antidepressants, atypical antipsychotics, treatment-resistant depression, weight gain, akathisia, tolerability, functional disability
- MeSH terms
- Adolescent, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Thiophenes, Antipsychotic Agents, Quinolones, Treatment Outcome, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.